argenx NV ADR (ARGX)

argenx NV ADR (ARGX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $54.9B; returns 1 day -0.2%, 1 week +6.7%, 1 year +7.6%.

argenx SE (ARGX) is a commercial-stage global immunology company based in the Netherlands, primarily focused on developing and commercializing antibody-based therapies for severe autoimmune diseases. Its core revenue driver is the VYVGART franchise, which includes both the intravenous (efgartigimod alfa-fcab) and subcutaneous (VYVGART Hytrulo) formulations.

Groups ARGX belongs to

• Biotechnology
• Autoimmune Diseases
• Commercial Stage Biotech
• Biopharmaceutical
• Antibody Therapeutics
• Healthcare
• Life Sciences
• Rare Diseases
• Monoclonal Antibodies
• Chronic Inflammatory Diseases
• Immunotherapy
• Pharmaceuticals

ARGX financial model: income statement, cash flow and balance sheet